Genmab A/S (VIE:GMAB)
Austria · Delayed Price · Currency is EUR | Market Cap | 14.06B +28.8% |
| Revenue (ttm) | 3.17B +19.2% |
| Net Income | 820.19M -15.0% |
| EPS | 13.09 -12.3% |
| Shares Out | n/a |
| PE Ratio | 17.14 |
| Forward PE | 20.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 229.20 |
| Previous Close | 229.30 |
| Day's Range | 227.50 - 229.20 |
| 52-Week Range | 163.70 - 302.40 |
| Beta | n/a |
| RSI | 43.20 |
| Earnings Date | May 7, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsNews
Genmab A/S Share Capital Reduction
Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital with ...
Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln
(RTTNews) - Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets...
Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026
Company Announcement Net sales of DARZALEX, in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026
Company Announcement Net sales of DARZALEX in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Bio...
Genmab (GMAB) Unveils Encouraging Data on New Ovarian Cancer Treatment
Genmab (GMAB) Unveils Encouraging Data on New Ovarian Cancer Treatment
Genmab A/S: Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer
Phase 1/2 RAINFOL-01 data showed the combination of rinatabart sesutecan (Rina-S) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The ongoing Pha...
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Media Release COPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ®) and bevacizumab was tolerable, with no new safety signals in pat...
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, top...
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) - This document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and...
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets ...
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 19, 2026, the Company's Board of Directors met to consti...
Genmab A/S Annual Shareholders Meeting Transcript
Genmab A/S Annual Shareholders Meeting Transcript
Passing of Genmab A/S' Annual General Meeting
Company Announcement At Genmab A/S' Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved Discharge was given to the Board of Directors and the Executive Management...
Completion of Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; March 16, 2026 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 13, 2026. On February 17, 2026, Genmab announ...
Genmab Transcript: Barclays 28th Annual Global Healthcare Conference
Three late-stage assets are set for pivotal readouts in 2026, with strong commercial and financial prospects driven by robust clinical data and expansion into broader patient populations. Direct commercialization in key markets and ongoing R&D are expected to sustain growth beyond the loss of major royalties.
Genmab Transcript: Leerink Global Healthcare Conference 2026
Strong financial performance and late-stage pipeline progress set the stage for major 2026 milestones, including pivotal trial readouts for EPKINLY, Rina-S, and petosemtamab. Commercial infrastructure is ready for launches in 2027, with each program targeting multi-billion dollar opportunities.
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 share...
Genmab Transcript: TD Cowen 46th Annual Health Care Conference
Strong recurring revenue growth and disciplined OpEx management are expected to continue through 2027, with EPKINLY driving near-term growth and new launches for Rina-S and Petosemtamab anticipated to contribute meaningfully from 2028. Peak sales targets for late-stage assets are set to offset potential royalty declines, while deleveraging and profitability remain key priorities.
Correction to Company Announcement No. 13 of March 2, 2026
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, thi...
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; February 27, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 587,495 restricted stock units to members of manage...
Genmab to Participate in Upcoming Investor Conferences
Media Release COPENHAGEN, Denmark; February 25, 2026 Genmab A/S (Nasdaq: GMAB) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor c...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The incr...